Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 4
1991 3
1992 6
1993 9
1994 14
1995 15
1996 18
1997 28
1998 21
1999 31
2000 72
2001 103
2002 132
2003 149
2004 201
2005 257
2006 319
2007 386
2008 367
2009 365
2010 369
2011 401
2012 431
2013 373
2014 383
2015 387
2016 380
2017 423
2018 337
2019 347
2020 340
2021 292
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

6,217 results
Results by year
Filters applied: . Clear all
Page 1
Pioglitazone.
Karásek D. Karásek D. Vnitr Lek. 2020 Spring;66(2):121-125. Vnitr Lek. 2020. PMID: 32942898 Review. English.
Pioglitazone belongs to the drugs primarily reducing insulin resistance. ...The paper provides an overview of cardiovascular clinical trials with pioglitazone, its safety profile and practical recommendations for its administration....
Pioglitazone belongs to the drugs primarily reducing insulin resistance. ...The paper provides an overview of cardiovascular clinical
Thiazolidinediones: the Forgotten Diabetes Medications.
Lebovitz HE. Lebovitz HE. Curr Diab Rep. 2019 Nov 27;19(12):151. doi: 10.1007/s11892-019-1270-y. Curr Diab Rep. 2019. PMID: 31776781 Free PMC article. Review.
RECENT FINDINGS: Recent studies indicate that cardiovascular toxicity with rosiglitazone and increase in bladder cancer with pioglitazone are no longer significant issues. There are new data which show that pioglitazone treatment reduces myocardial infarctions and i …
RECENT FINDINGS: Recent studies indicate that cardiovascular toxicity with rosiglitazone and increase in bladder cancer with pioglitazone
Pathophysiology-based treatment of urolithiasis.
Yasui T, Okada A, Hamamoto S, Ando R, Taguchi K, Tozawa K, Kohri K. Yasui T, et al. Int J Urol. 2017 Jan;24(1):32-38. doi: 10.1111/iju.13187. Epub 2016 Aug 18. Int J Urol. 2017. PMID: 27539983 Review.
Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes.
DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE. DeFronzo RA, et al. Diab Vasc Dis Res. 2019 Mar;16(2):133-143. doi: 10.1177/1479164118825376. Epub 2019 Feb 1. Diab Vasc Dis Res. 2019. PMID: 30706731 Free article. Review.
However, there is strong evidence that an older and now generically available medication, the thiazolidinedione, pioglitazone, can retard the atherosclerotic process (PERISCOPE and Chicago) and reduce cardiovascular events in large randomized prospective cardiovascular out …
However, there is strong evidence that an older and now generically available medication, the thiazolidinedione, pioglitazone, can re …
Recent advances in preventing recurrent stroke.
Spence JD. Spence JD. F1000Res. 2020 Aug 20;9:F1000 Faculty Rev-1012. doi: 10.12688/f1000research.23199.1. eCollection 2020. F1000Res. 2020. PMID: 32864099 Free PMC article. Review.
These include new evidence about nutrition, antiplatelet therapy, anticoagulation, lipid-lowering therapy, hypertension control, pioglitazone, and carotid endarterectomy and stenting. Evidence regarding toxic metabolites produced by the intestinal microbiome from egg yolk …
These include new evidence about nutrition, antiplatelet therapy, anticoagulation, lipid-lowering therapy, hypertension control, pioglita
Pioglitazone and bladder cancer risk: a systematic review and meta-analysis.
Tang H, Shi W, Fu S, Wang T, Zhai S, Song Y, Han J. Tang H, et al. Cancer Med. 2018 Apr;7(4):1070-1080. doi: 10.1002/cam4.1354. Epub 2018 Feb 24. Cancer Med. 2018. PMID: 29476615 Free PMC article.
Current evidence about the association between pioglitazone and bladder cancer risk remains conflict. We aimed to assess the risk of bladder cancer associated with the use of pioglitazone and identify modifiers that affect the results. ...Patients with long-term and …
Current evidence about the association between pioglitazone and bladder cancer risk remains conflict. We aimed to assess the risk of …
Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials.
de Jong M, van der Worp HB, van der Graaf Y, Visseren FLJ, Westerink J. de Jong M, et al. Cardiovasc Diabetol. 2017 Oct 16;16(1):134. doi: 10.1186/s12933-017-0617-4. Cardiovasc Diabetol. 2017. PMID: 29037211 Free PMC article. Review.
Pioglitazone did not reduce all-cause mortality (RR 0.94, 95% CI 0.81-1.08; I(2) = 0%), whereas pioglitazone treatment was associated with an increased risk of HF (RR 1.33, 95% CI 1.14-1.54). ...Pioglitazone does not lower the risk for all-cause mortality, an
Pioglitazone did not reduce all-cause mortality (RR 0.94, 95% CI 0.81-1.08; I(2) = 0%), whereas pioglitazone treatment was ass
Efficacy and safety of drugs for nonalcoholic steatohepatitis.
Shen B, Lu LG. Shen B, et al. J Dig Dis. 2021 Feb;22(2):72-82. doi: 10.1111/1751-2980.12967. J Dig Dis. 2021. PMID: 33385317 Review.
Lifestyle intervention is still the predominant treatment for NASH. So far, no drugs have been approved to treat NASH by the U.S. Food and Drug Administration (FDA). Vitamin E has been recommended for patients with NASH without type 2 diabetes mellitus (T2DM), whereas a co …
Lifestyle intervention is still the predominant treatment for NASH. So far, no drugs have been approved to treat NASH by the U.S. Foo …
Pioglitazone Exposure Reduced the Risk of All-Cause Mortality in Insulin-Treated Patients with Type 2 Diabetes Mellitus.
Yen FS, Wang HC, Pan CW, Wei JC, Hsu CC, Hwu CM. Yen FS, et al. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz026. doi: 10.1210/clinem/dgz026. J Clin Endocrinol Metab. 2020. PMID: 31544207
CONTEXT: The long-term safety and benefit of pioglitazone use in combination with insulin are still uncertain. OBJECTIVE: This study compared the risks of all-cause mortality and major cardiovascular (CV) events between pioglitazone users and nonusers receiving insu …
CONTEXT: The long-term safety and benefit of pioglitazone use in combination with insulin are still uncertain. OBJECTIVE: This study …
6,217 results